EVOTF News and Press, Evotec Ag Ord From 04/17/24

HAMBURG, GERMANY / ACCESSWIRE / April 17, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced the appointment of Aurélie Dalbiez as the Company's new Chief People Officer ("CPO"), effective 15 June 2024. Aurélie will be joining E...

CLARIS'S PORTFOLIO COMPANIES RECEIVE EASY ACCESS TO EVOTEC'S FULL RANGE OF PRE-CLINICAL AND CLINICAL DEVELOPMENT AND MANUFACTURING CAPABILITIES AGREEMENT BUILDS ON SUCCESSFUL COLLABORATION BETWEEN EVOTEC AND CLARIS'S PORTFOLIO COMPANY IAMA HAMBURG, GERMANY / TURIN, ITALY / ACCESSWIRE / ...

JUST - EVOTEC BIOLOGICS TO PROVIDE DEVELOPMENT AND PHASE I CLINICAL MANUFACTURING OF BROADLY NEUTRALISING ANTIBODY AGAINST HIV AGREEMENT BUILDS ON PREVIOUS NIAID-FUNDED COLLABORATION TO DEVELOP A BROADLY NEUTRALISING ANTIBODY AGAINST HIV HAMBURG, GERMANY / ACCESSWIRE / February 7, 2024 ...

2024-01-22 15:43:08 ET Evotec SE (EVO) Business Update Conference Call January 22, 2024, 09:00 AM ET Company Participants Volker Braun - SVP, Head of Global IR & ESG Iris Löw-Friedrich - Chairwoman Mario Polywka - Interim CEO Conference Call Partic...

HAMBURG, GERMANY / ACCESSWIRE / January 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) is going to hold a conference call to provide a statement as well as a business update on Monday, 22 January 2024. During the call, the Chairwoman of Evotec's...

EVOTEC JOINS FORCES WITH THE CROHN'S & COLITIS FOUNDATION'S IBD THERAPEUTICS INCUBATOR TO ADVANCE DRUG DISCOVERY AND IDENTIFY NOVEL THERAPIES FOR INFLAMMATORY BOWEL DISEASE ("IBD") THE COLLABORATION LEVERAGES EVOTEC'S END-TO-END INTEGRATED R&D PLATFORM TO ADVANCE DRUG DISCOVERY FOR T...

KEY SCIENTIFIC ACHIEVEMENT ADVANCES THE JOINT NEUROSCIENCE PIPELINE AND EARNS A PAYMENT OF US$ 25 M TO EVOTEC TO PROGRESS FURTHER RESEARCH HAMBURG, GERMANY / ACCESSWIRE / January 8, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced...

PARTNERSHIP COMBINES OWKIN'S A.I. TARGET DISCOVERY CAPABILITIES WITH EVOTEC'S INTEGRATED END-TO-END SHARED R&D PLATFORM A.I.-POWERED PLATFORMS WILL ACCELERATE OWKIN'S NOVEL PROGRAMMES FROM THE DISCOVERY PHASE TO THE CLINIC AGREEMENT INCLUDES SUCCESS-BASED MILESTONES AND ROYALTY PAYM...

HAMBURG, GERMANY / ACCESSWIRE / January 3, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ:EVO) announces that CEO Dr Werner Lanthaler has informed the company, that he has decided to step down as CEO and will not continue to...

EVOTEC JOINS THE BILL & MELINDA GATES FOUNDATION FUNDED GLOBAL HEALTH DISCOVERY COLLABORATORY ("GHDC") AS A NEW ADDITION TO THE FIFTEEN COLLABORATORY PLATFORMS GRANT FROM THE BILL & MELINDA GATES FOUNDATION PROVIDES GHDC MEMBER INSTITUTIONS WITH ACCESS TO EVOTEC'S IPSC-DERIVED HIGH-T...